SCHEMBL29608774

SCHEMBL29608774

Cc1ccc(S(=O)(=O)n2cc(-c3ccc(C(=O)N(C)CCC#N)cc3)c3nc(-c4cc(C)c5c(c4)CN(C)CC5)cnc32)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K1 Q92918 4/20 0.46
▸ ALDH1A1 P00352 3/20 0.39
▸ PTPN11 Q06124 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ MAPT P10636 1/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.31
▸ HSD17B10 Q99714 2/20 0.31
▸ UBE2N P61088 2/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ JAK2 O60674 1/20 0.31
▸ JAK1 P23458 1/20 0.31
▸ TYK2 P29597 1/20 0.31
▸ JAK3 P52333 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28709865 1.00 MAP4K1 (0.46) MAP4K1ALDH1A1PTPN11CYP1A2CYP3A4
SCHEMBL29607752 0.90 MAP4K1 (0.55) MAP4K1ALDH1A1PTPN11CYP1A2CYP3A4
SCHEMBL29608953 0.89 MAP4K1 (0.47) MAP4K1PTPN11CYP1A2CYP3A4CYP2D6
SCHEMBL29608109 0.89 MAP4K1 (0.56) MAP4K1PTPN11CYP1A2CYP3A4CYP2D6
SCHEMBL28709868 0.89 MAP4K1 (0.56) MAP4K1PTPN11CYP1A2CYP3A4CYP2D6
SCHEMBL29609249 0.89 MAP4K1 (0.56) MAP4K1PTPN11CYP1A2CYP3A4CYP2D6
SCHEMBL28709869 0.89 MAP4K1 (0.56) MAP4K1PTPN11CYP1A2CYP3A4CYP2D6
SCHEMBL28717476 0.89 MAP4K1 (0.56) MAP4K1PTPN11CYP1A2CYP3A4CYP2D6
SCHEMBL28706959 0.89 MAP4K1 (0.47) MAP4K1PTPN11CYP1A2CYP3A4CYP2D6
SCHEMBL22858740 0.88 MAP4K1 (0.52) MAP4K1ALDH1A1CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12454534-B2 Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof BEONE MEDICINES I GMBH (CH) 2025-10-28 — — US disclosed
US-20220267333-A1 PYRROLO[2,3-b]PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF BEONE MEDICINES I GMBH (CH) 2022-08-25 — — US disclosed
EP-3994136-A1 PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF BeiGene, Ltd. (KY) 2022-05-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220267333-A1 PYRROLO[2,3-b]PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF PDXK, STK25, STK35 MAP4K1 82/4885ALDH1A1 3320/4885PTPN11 593/4885
US-12454534-B2 Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof PDXK, STK25, STK35 MAP4K1 82/4885ALDH1A1 3320/4885PTPN11 593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback